JOP20200098A1 - طرق علاج الفشل القلبي مع كسر قذفي منخفض بواسطة داباجليفلوزين - Google Patents

طرق علاج الفشل القلبي مع كسر قذفي منخفض بواسطة داباجليفلوزين

Info

Publication number
JOP20200098A1
JOP20200098A1 JOP/2020/0098A JOP20200098A JOP20200098A1 JO P20200098 A1 JOP20200098 A1 JO P20200098A1 JO P20200098 A JOP20200098 A JO P20200098A JO P20200098 A1 JOP20200098 A1 JO P20200098A1
Authority
JO
Jordan
Prior art keywords
heart failure
dapagliflozin
ejection fraction
methods
treating heart
Prior art date
Application number
JOP/2020/0098A
Other languages
English (en)
Inventor
Maria Langkilde Anna
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of JOP20200098A1 publication Critical patent/JOP20200098A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

يتعلق الكشف الحالي بطرق علاج مرضى الفشل القلبي مع كسر قذفي منخفض (HFrEF)، مع وبدون السكري من النوع 2، بواسطة مثبط SGLT2، مثل داباجليفلوزين. يمكن أن تقوم الطرق المكشوف عنها هنا بخفض خطر ناتج مركب من سلسلة أولى من زيادة سوء الفشل القلبي (دخول المشفى بسبب الفشل القلبي أو زيارة طارئة بسبب الفشل القلبي) أو وفاة من أسباب قلبية وعائية. يمكن أيضا خفض كل من المكونات الثلاثة للناتج المركب هذا، بالإضافة إلى العدد الكلي لحالات دخول المشفى والوفيات بسبب الفشل القلبي من أسباب قلبية وعائية. يمكن أن تقوم مثبطات SGLT2، مثل داباجليفلوزين، أيضا بخفض زيادة سوء أعراض الفشل القلبي. يمكن أيضا أن تقوم الطرق المكشوف عنها هنا بتحسين أعراض الفشل القلبي، الحالة الصحية، وجودة الحياة.
JOP/2020/0098A 2019-08-30 2020-03-09 طرق علاج الفشل القلبي مع كسر قذفي منخفض بواسطة داباجليفلوزين JOP20200098A1 (ar)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962893849P 2019-08-30 2019-08-30
US201962930673P 2019-11-05 2019-11-05
US201962946625P 2019-12-11 2019-12-11
US202062960756P 2020-01-14 2020-01-14
US202062969181P 2020-02-03 2020-02-03
US202062985407P 2020-03-05 2020-03-05
PCT/EP2020/056211 WO2021037400A1 (en) 2019-08-30 2020-03-09 Methods of treating heart failure with reduced ejection fraction with dapagliflozin

Publications (1)

Publication Number Publication Date
JOP20200098A1 true JOP20200098A1 (ar) 2021-02-28

Family

ID=69784449

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0098A JOP20200098A1 (ar) 2019-08-30 2020-03-09 طرق علاج الفشل القلبي مع كسر قذفي منخفض بواسطة داباجليفلوزين

Country Status (18)

Country Link
US (3) US10973836B2 (ar)
EP (1) EP4021507A1 (ar)
JP (4) JP7756487B2 (ar)
KR (3) KR102359799B1 (ar)
CN (1) CN112752582A (ar)
AU (4) AU2020202887B2 (ar)
BR (1) BR112020008705A2 (ar)
CA (1) CA3079175A1 (ar)
CL (1) CL2020001335A1 (ar)
CR (1) CR20200224A (ar)
IL (1) IL274020A (ar)
JO (1) JOP20200098A1 (ar)
MX (2) MX2020005388A (ar)
PE (1) PE20211267A1 (ar)
PH (1) PH12020551141A1 (ar)
SG (1) SG11202003971RA (ar)
TW (3) TW202504616A (ar)
WO (1) WO2021037400A1 (ar)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53175A (fr) 2018-07-19 2021-05-26 Astrazeneca Ab Méthodes de traitement de hfpef au moyen de dapagliflozine et compositions comprenant celle-ci
PE20211267A1 (es) * 2019-08-30 2021-07-19 Astrazeneca Ab Metodos de tratamiento de la insuficiencia cardiaca con fraccion de eyeccion reducida con dapagliflozina
CA3180674A1 (en) * 2020-04-22 2021-10-28 Bayer Aktiengesellschaft Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
WO2022144465A1 (en) * 2021-01-04 2022-07-07 Charité-Universitätsmedizin Berlin Sotagliflozin for improving left atrial function
US20250108065A1 (en) 2022-01-26 2025-04-03 Astrazeneca Ab Methods of treating prediabetes or reducing the risk of developing type 2 diabetes with dapagliflozin
JP7396579B2 (ja) * 2022-01-31 2023-12-12 壽製薬株式会社 左室駆出率が保たれた心不全に対する医薬組成物
WO2023175573A1 (en) * 2022-03-17 2023-09-21 Zydus Lifesciences Limited Pharmaceutical compositions comprising a β-blocker and an sglt2 inhibitor
WO2023192848A1 (en) * 2022-03-28 2023-10-05 University Of Maryland, Baltimore Methods and compositions for the treatment of stroke
AU2023331475A1 (en) * 2022-09-01 2025-04-17 Astrazeneca Ab Combination of sglt2 inhibitors and mineralcorticoid receptor modulators for use in treatment of cardiorenal diseases
CN120390636A (zh) * 2022-12-20 2025-07-29 斯法姆公司 包含钠-葡萄糖协同转运蛋白2抑制剂和血管紧张素ⅱ受体阻滞剂的口服药物制剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
AR059489A1 (es) 2006-02-15 2008-04-09 Boehringer Ingelheim Vetmed Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
TW200904405A (en) * 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
TW200904454A (en) * 2007-03-22 2009-02-01 Bristol Myers Squibb Co Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
JP2011506363A (ja) 2007-12-11 2011-03-03 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 心不全の処置および／または予防用のオキサゾリジノン類
CA2812016A1 (en) * 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP3160948B1 (en) 2014-06-30 2018-10-24 Astrazeneca AB Benzoxazinone amides as mineralocorticoid receptor modulators
CN106714840A (zh) * 2014-09-25 2017-05-24 阿斯利康(瑞典)有限公司 用于治疗肝病的ω‑3脂肪酸和SGLT‑2抑制剂的组合
BR112018016001A2 (en) * 2016-03-16 2018-12-18 Boehringer Ingelheim International Gmbh pharmaceutical composition, treatment methods and uses thereof
WO2018043463A1 (ja) * 2016-08-30 2018-03-08 国立大学法人新潟大学 老化細胞除去薬
WO2018142422A1 (en) 2017-02-02 2018-08-09 Indoco Remedies Limited Process for the preparation of dapagliflozin
KR101943382B1 (ko) 2017-09-19 2019-01-29 오토텔릭바이오 주식회사 Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
MA53175A (fr) 2018-07-19 2021-05-26 Astrazeneca Ab Méthodes de traitement de hfpef au moyen de dapagliflozine et compositions comprenant celle-ci
PE20211267A1 (es) 2019-08-30 2021-07-19 Astrazeneca Ab Metodos de tratamiento de la insuficiencia cardiaca con fraccion de eyeccion reducida con dapagliflozina
US12409186B2 (en) * 2020-07-27 2025-09-09 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin

Also Published As

Publication number Publication date
TWI859649B (zh) 2024-10-21
PE20211267A1 (es) 2021-07-19
TWI786398B (zh) 2022-12-11
TW202335668A (zh) 2023-09-16
JP7494277B2 (ja) 2024-06-03
BR112020008705A2 (pt) 2022-03-22
JP2024119842A (ja) 2024-09-03
PH12020551141A1 (en) 2021-05-31
US10973836B2 (en) 2021-04-13
JP2022530575A (ja) 2022-06-30
TW202108134A (zh) 2021-03-01
CA3079175A1 (en) 2021-02-28
AU2021215150A1 (en) 2021-09-02
SG11202003971RA (en) 2021-04-29
AU2023210548A1 (en) 2023-08-17
AU2023210548B2 (en) 2025-04-17
IL274020A (en) 2021-03-01
KR20220044234A (ko) 2022-04-07
JP7756487B2 (ja) 2025-10-20
CR20200224A (es) 2021-05-26
TW202504616A (zh) 2025-02-01
US20210260083A1 (en) 2021-08-26
CN112752582A (zh) 2021-05-04
KR20240166611A (ko) 2024-11-26
AU2021215150B2 (en) 2023-05-04
CL2020001335A1 (es) 2021-07-09
MX2020005388A (es) 2022-10-25
JP2025108488A (ja) 2025-07-23
US20210060043A1 (en) 2021-03-04
MX2022008018A (es) 2022-07-27
EP4021507A1 (en) 2022-07-06
AU2020202887A1 (en) 2021-03-18
AU2020202887B2 (en) 2021-05-20
KR20210027229A (ko) 2021-03-10
WO2021037400A1 (en) 2021-03-04
AU2025204486A1 (en) 2025-07-03
US20240216404A1 (en) 2024-07-04
JP2023025207A (ja) 2023-02-21
US11903955B2 (en) 2024-02-20
KR102359799B1 (ko) 2022-02-09

Similar Documents

Publication Publication Date Title
JOP20200098A1 (ar) طرق علاج الفشل القلبي مع كسر قذفي منخفض بواسطة داباجليفلوزين
Zheng et al. Mitochondrial regulation of stem cells in bone homeostasis
Ugusman et al. Role of rutin on nitric oxide synthesis in human umbilical vein endothelial cells
Mack et al. Epidemiology, traditional and novel risk factors in coronary artery disease
BR112022009216A2 (pt) Métodos e composições para tratar um distúrbio associado a angiotensinogênio (agt)
Boström et al. Impact of exercise on muscle and nonmuscle organs
MX2026002043A (es) Combinacion de los compuestos ch5126766 y vs-6063 para usarse en el tratamiento de cancer
EP4219712A3 (en) Nucleic acids for inhibiting expression of lpa in a cell
BR112018002046A2 (pt) métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina
MX2024009873A (es) Construcciones de arni para inhibir expresion de asgr1 y metodos para su uso.
Sanchis-Gomar et al. New molecular targets and lifestyle interventions to delay aging sarcopenia
PH12017500977A1 (en) 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4h-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
BR112021008094A2 (pt) Métodos de tratamento de doença renal crônica com dapagliflozina
Shaheen et al. Cardiovascular and cerebrovascular comorbidities in hemodialysis patients from the Gulf Cooperation Council countries enrolled in the dialysis outcome and practice pattern study phase 5 (2012–2015)
BR112016028750A2 (pt) ?métodos para tratar, prevenir, ou melhorar pelo menos um sintoma associado e para diagnosticar e monitorar insuficiência cardíaca ou fibrilação atrial, inibidor da lisil oxidase ativa ou proteína lisil tipo oxidase, e, composição?
Chen et al. Severe pulmonary arterial hypertension secondary to lupus in the emergency department: proactive intense care associated with a better short‐term survival
BR112017024065A2 (pt) método para tratar insuficiência cardíaca avançada em um indivíduo humano
EA202090875A1 (ru) Способы лечения сердечной недостаточности со сниженной фракцией выброса с помощью дапаглифлозина
EA201890213A1 (ru) Съедобная композиция
Alpay Boosting NAD+ for Anti-Aging: Mechanisms, Interventions, and Opportunities
Czubatka-Bienkowska et al. The oxidative induction of DNA lesions in cancer cells by 5-thio-d-glucose and 6-thio-d-fructopyranose and their genotoxic effects. Part 3
ATE479371T1 (de) Kochvorrichtung
BR112020012668A8 (pt) Composição para o tratamento de um paciente com doença respiratória associada a inflamações crônicas e método de produção e utilização da composição
AR118963A1 (es) Métodos de tratamiento de la insuficiencia cardíaca con fracción de eyección reducida con dapagliflozina
Sun et al. NOD2 agonist promotes the production of inflammatory cytokines in VSMC in synergy with TLR2 and TLR4 agonists